Codexis Future Growth
Future criteria checks 1/6
Codexis is forecast to grow earnings and revenue by 41.7% and 19.2% per annum respectively while EPS is expected to grow by 52.8% per annum.
Key information
41.7%
Earnings growth rate
52.8%
EPS growth rate
Life Sciences earnings growth | 17.7% |
Revenue growth rate | 19.2% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 15 Aug 2024 |
Recent future growth updates
Recent updates
After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar
Jul 26Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Jul 12Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects
May 29Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Codexis gets new executive chief
Jul 18Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?
Jul 06Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 88 | -28 | -20 | N/A | 3 |
12/31/2025 | 66 | -54 | -39 | N/A | 7 |
12/31/2024 | 65 | -54 | -60 | N/A | 8 |
6/30/2024 | 61 | -76 | -49 | -47 | N/A |
3/31/2024 | 74 | -65 | -54 | -51 | N/A |
12/31/2023 | 70 | -76 | -57 | -53 | N/A |
9/30/2023 | 74 | -82 | -41 | -37 | N/A |
6/30/2023 | 99 | -57 | -6 | -1 | N/A |
3/31/2023 | 116 | -48 | 8 | 13 | N/A |
12/31/2022 | 139 | -34 | 3 | 11 | N/A |
9/30/2022 | 133 | -31 | -7 | 7 | N/A |
6/30/2022 | 135 | -19 | -29 | -13 | N/A |
3/31/2022 | 122 | -21 | -35 | -19 | N/A |
12/31/2021 | 105 | -21 | -28 | -14 | N/A |
9/30/2021 | 101 | -15 | -26 | -16 | N/A |
6/30/2021 | 83 | -23 | -26 | -20 | N/A |
3/31/2021 | 72 | -25 | -27 | -21 | N/A |
12/31/2020 | 69 | -24 | -20 | -16 | N/A |
9/30/2020 | 67 | -21 | -21 | -19 | N/A |
6/30/2020 | 70 | -14 | -20 | -16 | N/A |
3/31/2020 | 68 | -14 | -15 | -11 | N/A |
12/31/2019 | 68 | -12 | -16 | -13 | N/A |
9/30/2019 | 66 | -12 | -14 | -10 | N/A |
6/30/2019 | 61 | -14 | -12 | -10 | N/A |
3/31/2019 | 62 | -11 | -16 | -13 | N/A |
12/31/2018 | 61 | -11 | -17 | -14 | N/A |
9/30/2018 | 66 | -9 | -8 | -6 | N/A |
6/30/2018 | 59 | -18 | -11 | -9 | N/A |
3/31/2018 | 56 | -20 | N/A | -9 | N/A |
12/31/2017 | 50 | -23 | N/A | -9 | N/A |
9/30/2017 | 38 | -29 | N/A | -12 | N/A |
6/30/2017 | 43 | -18 | N/A | -14 | N/A |
3/31/2017 | 49 | -9 | N/A | -6 | N/A |
12/31/2016 | 49 | -9 | N/A | -2 | N/A |
9/30/2016 | 50 | -5 | N/A | 0 | N/A |
6/30/2016 | 53 | -1 | N/A | 8 | N/A |
3/31/2016 | 43 | -9 | N/A | 4 | N/A |
12/31/2015 | 42 | -8 | N/A | 0 | N/A |
9/30/2015 | 44 | -5 | N/A | -3 | N/A |
6/30/2015 | 34 | -15 | N/A | -1 | N/A |
3/31/2015 | 35 | -18 | N/A | -1 | N/A |
12/31/2014 | 35 | -19 | N/A | 0 | N/A |
9/30/2014 | 31 | -29 | N/A | -9 | N/A |
6/30/2014 | 27 | -34 | N/A | -19 | N/A |
3/31/2014 | 28 | -38 | N/A | -22 | N/A |
12/31/2013 | 32 | -41 | N/A | -23 | N/A |
9/30/2013 | 30 | -47 | N/A | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CDXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CDXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CDXS's revenue (19.2% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: CDXS's revenue (19.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDXS's Return on Equity is forecast to be high in 3 years time